Related Experiment Video
Updated: Aug 30, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells
L-M Sturla1, A E Merrick, S A Burchill
1Candlelighter's Children's Cancer Research Laboratory, Cancer Research UK Clinical Centre, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Abstract:
Fibroblast growth factor receptor 3 (FGFR3) is one of four high-affinity tyrosine kinase receptors for the FGF family of ligands, frequently associated with growth arrest and induction of differentiation. The extracellular immunoglobulin (IgG)-like domains II and III are responsible for ligand binding; alternative usage of exons IIIb and IIIc of the Ig-like domain III determining the ligand-binding specificity of the receptor. By reverse transcriptase polymerase chain reaction (RT-PCR) a novel FGFR3IIIc variant FGFR3IIIS, expressed in a high proportion of tumours and tumour cell lines but rarely in normal tissues, has been identified. Unlike recently described nonsense transcripts of FGFR3, the coding region of FGFR3IIIS remains in-frame producing a novel protein. The protein product is coexpressed with FGFR3IIIc in the membrane and soluble cell fractions; expression in the soluble fraction is decreased after exposure to bFGF but not aFGF. Knockout of FGFR3IIIS using antisense has a growth-inhibitory effect in vitro, suggesting a dominant-negative function for FGFR3IIIS inhibiting FGFR3-induced growth arrest. In summary, alternative splicing of the FGFR3 Ig-domain III represents a mechanism for the generation of receptor diversity. FGFR3IIIS may regulate FGF and FGFR trafficking and function, possibly contributing to the development of a malignant phenotype.
Insights
A novel Fibroblast Growth Factor Receptor 3 (FGFR3) variant, FGFR3IIIS, was identified. This variant may inhibit FGFR3-induced growth arrest, potentially contributing to cancer development.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Fibroblast Growth Factor Receptor 3 (FGFR3) is a tyrosine kinase receptor involved in cell growth and differentiation.
- Ligand binding specificity is determined by alternative splicing of exons IIIb and IIIc in the FGFR3 Ig-like domain III.
- Aberrant FGFR3 signaling is implicated in various cancers.
Purpose of the Study:
- To identify and characterize novel FGFR3 variants.
- To investigate the functional role of the newly identified FGFR3IIIS variant.
- To explore the potential contribution of FGFR3IIIS to malignant phenotypes.
Main Methods:
- Reverse transcriptase polymerase chain reaction (RT-PCR) for variant identification.
- Analysis of protein expression in membrane and soluble cell fractions.
- In vitro studies using antisense technology to assess functional impact.
Main Results:
- A novel FGFR3IIIc variant, FGFR3IIIS, was identified, predominantly expressed in tumors.
- FGFR3IIIS produces a novel, in-frame protein coexpressed with FGFR3IIIc.
- Knockout of FGFR3IIIS demonstrated in vitro growth inhibition, suggesting a dominant-negative function.
Conclusions:
- Alternative splicing of FGFR3 Ig-domain III generates receptor diversity.
- FGFR3IIIS may play a regulatory role in FGF and FGFR trafficking and function.
- FGFR3IIIS is a potential contributor to the development of a malignant phenotype.
Related Concept Videos
TGF - β Signaling Pathway
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
RNA Splicing
Abnormal Proliferation

